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Abstract
Molecularly targeted agents for the treatment of solid tumors had entered the market in the last 5
years, with a great impact upon both the scientific community and the society. Many randomized
phase III trials conducted in recent years with new targeted agents, despite previous data coming
from preclinical research and from phase II trials were often promising, have produced
disappointingly negative results. Some other trials have actually met their primary endpoint,
demonstrating a statistically significant result favouring the experimental treatment. Unfortunately,
with a few relevant exceptions, this advantage is often small, if not negligible, in absolute terms. The
difference between statistical significance and clinical relevance should always be considered when
translating clinical trials' results in the practice. The reason why this 'revolution' did not significantly
impact on cancer treatment to displace chemotherapy from the patient' bedside is in part due to
complicated, and in many cases, unknown, mechanisms of action of such drugs; indeed, the
traditional way the clinical investigators were used to test the efficacy of 'older' chemotherapeutics,
has become 'out of date' from the methodological perspective. As these drugs should be
theoretically tailored upon featured bio-markers expressed by the patients, the clinical trial design
should follow new rules based upon stronger hypotheses than those developed so far. Indeed, the
early phases of basic and clinical drug development are crucial in the correct process which is able
to correctly identify the target (when present). Targeted trial designs can result in easier studies,
with less, better selected, and supported by stronger proofs of response evidences, patients, in
order to not waste time and resources.
Introduction
The increasing amount of knowledge about biological tar-
gets is nowadays going to switch the balancing and equi-
librium between the medicine for the 'entire population'
and the medicine for 'the individual', in favour of the lat-
ter, in order to better aim to a modern concept of 'ideal
medicine'. The results obtained with the traditional clini-
cal trial design with molecularly targeted agents so far are
far from being optimal. Indeed, with the exception of tras-
tuzumab for breast cancer, we observe 4 common out-
come patterns of randomized trials in solid tumors: 1)
studies reporting a significant while small survival benefit
for the targeted agent (advanced pretreated non-small-cell
lung cancer, NSCLC, erlotinib versus placebo) [1]; 2)
studies reporting a significant while minimal survival ben-
efit for the targeted agent (advanced untreated pancreatic
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citabine) [2]; 3) studies reporting no significant differ-
ences in survival (advanced pretreated NSCLC, gefitinib
versus placebo) [3]; and 4) studies reporting an unex-
pected significantly detrimental effect of the targeted
agent (locally advanced NSCLC, maintenance gefinitib
after chemotherapy versus placebo) [4]. Given these sce-
narios, no major differences in the trials results with (old)
and so-considered 'un-targeted' chemotherapeutics do
appear, with the exception of trastuzumab.
Targeted versus untargeted design for new 
drugs
What is wrong with this design approach when molecu-
larly targeted agents are tested? The 'new age' of medical
oncology is experiencing many biological advances and
discoveries from the basic science side and the new avail-
able techniques, concurrently with the release of new
available drugs. Moreover, medical oncology represents
the field of clinical medicine with the higher failure-rate
for late-stage clinical trials, when compared to the other
specialties, and with the higher time- and resource-inten-
sive process, with more than 800 million US dollars to
bring a new drug to market.
So, the clinical trial design methodology needs to be
updated, given the 'confusion' provided by the discovery
of new targets, which identify (in many cases) new
patient' subgroups. For these reasons, it seems reasonable
to ask ourselves, among a high number of other relevant
questions, if: 1) response rate is an adequate end-point for
phase II trials with molecularly targeted agents; 2) the ran-
domized phase II fashion represents a real step beyond;
and 3) which kind of phase III do we need. On the other
hand, we should restrict this 'revision' of the design
approach to those drugs with a known targeted popula-
tion (and so apply a 'targeted-design'), and do not discard
the traditional way for drugs without a clear beneficial
patient' group (and so apply an 'untargeted-design').
The metastatic breast cancer scenario do offer both
options: the trastuzumab and the bevacizumab registra-
tion trials [5,6]. Trastuzumab entered the market thanks
to a relatively small trial (469 patients), while able to
determine a huge survival difference (5 months); if a tra-
ditional untargeted design would have been adopted,
considering a 20–30% prevalence of the HER-2 positive
population, and a treatment effect of 10% benefit, more
than 23 thousands of patients would have been required
[7]! Conversely, although the untargeted approach used
for bevacizumab allowed to register the drug with a signif-
icant (while absolutely small) benefit in progression-free
survival, retrospective evidences are emerging indicating
those subset of patients where the benefit is maximized,
on the basis of genetic variants [8].
The role of 'early phases': are traditional phase I 
studies with new drugs reliable?
Traditional phase I studies for chemotherapeutic agents are
designed to find the maximum tolerated dose (MTD) and
the dose-limiting toxicity (DLT) of the drugs. The assump-
tions underlying phase I designs are that for most cytotoxic
agents there is a direct relationship between the dose of a
drug, its antitumor effect and toxicity. Therefore, toxicity
and activity increase with the increasing of the dose of the
drug and there is a recommended dose that provides clini-
cal activity with acceptable toxicity. Thus, toxicity has been
seen as a surrogate for potentially effective doses. With bio-
logical agents, acting on highly specific targets expressed in
cancer cells, the MTD may not be reached if the drug has a
much wider therapeutic ratio: therefore, an increase of the
doses to toxic levels may be not necessary to achieve the
maximum activity and it may be an irrelevant end point.
There are alternative end points for these agents that can be
usefully employed in phase I studies: the identification of a
molecular drug effect (the 'target effect'), the measurement
of 'surrogates' for biological activity and the assessment of
drug plasma levels. The identification of the 'target effect'
through pharmacodynamic assays is proof of principle and
can be proof of activity of the drug. The main application of
pharmacodynamic studies is to help in the selection of the
minimum target inhibiting dose (MTID) and the optimal
schedule of administration of a drug [9].
The role of 'early phases': what about phase II 
studies?
An 'average' drug development time-process performed
by the best multicenter, cooperative, skilled, international
group, which is constituted by a 1-year phase I to find the
safe dose of the new drug and its toxicities, a 1–2 years for-
mal phase II to test the activity and the tolerability (on the
basis of an hypothesis formulated on historical data), and
a 2–5 years classical phase III to see how the drug compare
with the standard, will result into, at least, a 5 years long
course. With this 'favourable' described perspective, it easy
to understand that the role of the early phases (preclinical,
phase I and II) is crucial in order to have a positive results
in the forthcoming phase III. After a good (and independ-
ent, unbiased) preclinical development, within the first
1–3 year of the clinical development it is easy to control
the drug effect, to monitor either the biological and the
clinical action, and to identify the exact target (when
present). Moreover, this is the moment when it is possible
to screen for all putative surrogate biological end-points.
When a drug enter the phase II study, is difficult to obtain
all these informations, given the present statistical bor-
ders; only stopping rules into pre-planned interim analy-
ses are allowed (with all their related concerns).
What are the limitations in the phase II study design? A
single-arm formal phase II is designed upon response lim-Page 2 of 7
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rience of standard treatment, which constitute the
benchmark response rate. The choice of such border is
influenced by several biases, according to the recent report
by Vickers et al [10]. When appropriate criteria for citation
of prior data are fixed, those studies that met them were
significantly less likely to reject the null hypotheses (33%)
than those cited that did not meet the criteria (33% versus
85%, respectively; p = 0.006) [10]. With this perspective,
it seems that the decision to go into a phase III is biased
by not accurate reporting of historical data. By this, if
wrong hypothesis is tested, the chance of a positive, relia-
ble result into the following phase III is reduced; unbiased
evidences with accurate testing hypotheses are needed to
improve the success rate of a new drug in a randomized
trial [11].
Do we have predictors of success in the subsequent phase
III, into the phase II studies? A recent analysis of a series
of phase II with molecularly targeted agents reports that
the presence of positive results (p = 0.027), the sponsor-
ship of a pharmaceutical company (p = 0.014), the short
interval between the publication of phase II and III (p <
0.001) and multi-institutional trials (p = 0.016), are all
independent predictors of success at the multivariate anal-
ysis [12]. Another important finding (which is commonly
reproduced in many phase II studies with molecularly tar-
geted agents) is that if the rate of disease progression is
chosen as measure of drug effect instead of the 'classical'
response rate, the chance of a positive following phase III
is higher [12].
'Myths' of targeted agents: activity or efficacy as 
phase II primary end-point?
At least two 'myths' are perceived to be specific features of
molecularly targeted agents. The first one is that, con-
versely to classical cytotoxics, molecularly targeted agents
would selectively hit a specific molecule or enzyme and
that their functional and clinical effects would be directly
related to the level of target inhibition. A recent exhaustive
review by Karaman et al visually shows that the many
commonly used TKIs (tyrosine-kinase inhibitors) may hit
several intracellular pathways (for example sunitinib),
while others really seem to restrict their action upon one
proliferation pattern (for example lapatinib), by elegantly
using kinase dendrograms [13]. It would be interesting to
understand how much the classical cytotoxic differs in
such kind of analysis from the so-called 'targeted' agents.
Recent reports strongly enhance the potential 'targeting' of
old chemotherapeutics [14].
The second 'myth' to discard is that molecularly targeted
agents are 'cytostatic' in nature, i.e. they will slow down
growth, but seldom shrink pre-existing tumor masses.
That seems true for sorafenib in hepatocellular carcinoma,
where no major difference in both responses and disease
stabilization are present between patients receiving such
drug and those undergone placebo [15]. Nevertheless, this
trial returns in suggesting that these drugs show much
more benefit in efficacy end-points rather than old-classi-
cal activity (at least measured as we are used to so far);
indeed, the benefit in both radiological progressions and
overall survival is statistically significant [15]. Conversely,
this assumptions falls down for sunitinib in advanced
renal cell carcinoma, where patients receiving such drug
show a dramatic difference in responses when compared
to interferon, with no difference in disease stabilization
[16]. Besides, the benefit is confirmed with much more
efficiency in progression-free-surivival and in overall-sur-
vival in the censored analysis, taking into account the
cross-over [16,17]. The mentioned assumption is again to
be considered as false if patients are selected on the basic
of molecular features. A phase II study conducted to test
the activity of erlotinib in advanced pretreated NSCLC
patients displaying the mutation of the EGFR gene, shows
an overall response rate of 82%, ten-fold greater of what
we are used to see in such setting if not selected on the
basis of molecular features [18]. Although this is a phase
II study, these data are impressive.
Phase II randomized studies: a new tale with 
targeted agents
One other bias of single-arm classical phase II is that the
obtained response rate could be better owing to the
patient selection (even when the historical benchmark
border is correctly chosen). How this problem could be
overcome? A solution is offered by randomized phase II,
where, according to selection design, multiple experimen-
tal drugs or regimens are concurrently tested together, and
the winner (with regard to the outcome) is 'picked' and
proposed for the further phase III study. These studies are
currently misinterpreted due to not-allowed or compari-
son, although not adequately dimensioned for any sur-
vival (or other efficacy outcome) difference. The overall
number of such studies has significantly increased with
the introduction of new drugs, as reported in the analysis
performed by El-Maraghi et al, in which is reported that
overall response are still used as activity parameter for
molecular agents, and it is predictor of success in phase III,
in a series of 89 studies [19]; 30% of such studies are
designed in a randomized fashion.
So far, the randomized phase II trial had to: 1) test exper-
imental drugs or combination, and pick the winner for
further phase III; 2) be aimed to safety and activity (i.e.
response rates); 3) do not use survival end-points; and
finally 4) never compare treatment arms. What about new
molecularly targeted agents from now on? The issue
should be approached balancing risks and benefits
between two options. If we use the randomization as aPage 3 of 7
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rate results from early studies with molecularly targeted
agents, what is less dangerous? An uncontrolled single-
arm phase II, with response as end-point, or a controlled
multiple-arm randomized phase II, with survival (or sim-
ilar efficacy parameter) as end-point. Taking into account
the issues raised by Ratain et al [11], uncontrolled designs
(i.e. 'classical' phase II), have high efficiency in identifying
non-active drugs (high negative predictive value), but low
efficiency in selecting the best challengers for phase III
(low positive predictive value), while controlled designs
(i.e. 'comparative' phase II randomized) have increases
positive predictive value, should be (must be) conducted
with permissive statistical error criteria (higher alfa-error),
and must be followed (if positive) by a classical phase III
with traditional rules.
Recently, some authors have encouraged randomized
design for phase II trials, to allow a formal comparison
between experimental and standard treatment. This
should lead to a better interpretation of the results
obtained with the experimental treatment that are in most
cases difficult to interpret in the absence of control. Of
course, the adoption of a randomized design should not
transform a phase II into a phase III trial, because the lat-
ter is characterized by more stringent criteria, requiring a
sample size that would be too large and inappropriate for
the early evaluation of an experimental treatment. Rand-
omized phase II trials could instead be conducted accord-
ing to so-called 'relaxed' criteria, with a power not
exceeding 80% and one-tailed alpha error set to 15% or
20%, much higher than commonly accepted [11,20].
Such a high risk of false positive results, which would be
of course unacceptable in a phase III trial, can be accepta-
ble in this early context, leading to small sample sizes, to
quickly select promising treatments that will be subse-
quently tested for efficacy. According to some authors,
randomized phase II trials may become the standard
approach for development of targeted drugs and should
be designed with explicit comparative intent [21]. A pecu-
liar type of randomized phase II trial is the so-called "ran-
domized discontinuation design" (RDD) [22,23]. After a
first stage in which all patients receive the experimental
drug, in the second stage only patients with stable disease
are randomized to receive placebo or the active drug. RDD
was created with the aim of better interpreting the cause/
effect relationship between drug administration and dis-
ease stabilization, which is potentially related to treat-
ment-induced growth delay and to enrich the study
population for responsive subjects. In the RDD, the com-
parison between patients shifting to placebo and patients
continuing the drug should allow to understand whether
the stabilization achieved in those patients was simply
related to the natural history of disease or due to treat-
ment activity.
Targeted agents: moving to phase III trials
Moving to phase III trials with new molecularly targeted
agents, few considerations must be done: the vast majority
of cancer therapies do benefit only a patient' subgroup
between all patients those are administered. If we will be
able to target treatment upon the right patients we will
maximize the benefit of treated patients, we will provide
treatments more cost-effective for the entire society, and
finally (but more relevant for clinical research) we will get
more informations for successful clinical trials.
The vast majority of informations regarding the eventual
preferential effect of a molecularly targeted agents on a
specific molecular features, whatever it is, mutation, over-
exspression or amplification, is provided by retrospective
analyses of large randomized trials exploring the benefit
of the adopted new drugs into a unselected population.
Thereafter, subgroup analyses (mainly unplanned) are
performed, and, for those characteristics requiring tissue
and/or blocks, these are done on even small samples, i.e.
in those patients where the tissue is available. With these
perspectives, it sees rather obvious that any conclusions
should be softened are weighted with the real statistical
power of the original analysis which the trial is design for.
The results of the recent trial exploring the effect of cetux-
imab over best supportive care (BSC) in advanced pre-
treated colorectal cancer patients according to the k-RAS
gene mutation are consistent with those recently pre-
sented at the last ASCO meeting, which restrict the benefit
of cetuximab to wild-type patients [24-26]. k-RAS status
seem to not have any prognostic role in OS in patients
receiving BSC, while in the trial recently published by
Amado et al, a prognostic effect of the k-RAS status is
present in the BSC arm in comparison to panitumumab
[27]. These data stress the controversy in the data interpre-
tation process of retrospective analyses for clinical prac-
tice.
Nevertheless, conducting a phase III trial in the traditional
manner without strict eligibility criteria may result in a
false negative trial, unless a sufficiently large part of the
treated patients have tumors were by the target is
expressed. So, the more the target is underrepresented in
the original sample, the more the chance to find right
answer decreases. Greater emphasis should be probably
given, when planning a clinical trial and when interpret-
ing its results, to the great impact that the molecular het-
erogeneity of tumors, affecting sensitivity to the
experimental treatment, may have on the results of a clin-
ical trial [28]. This concept has been never taken into
account in the planning and the analysis of clinical trials
with cytotoxic agents, but it should be necessarily consid-
ered in clinical trials with molecularly targeted agents. In
a simplified situation, in which the whole population ofPage 4 of 7
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where genotype A is characterized by sensitivity to the
experimental treatment producing in this group an out-
come better than in the control group, and the genotype B
is characterized by absence of difference in efficacy
between experimental and standard treatment – the
higher the proportion of patients with genotype B in the
study sample, the lower the power of the clinical trial to
show a positive result. The statistical power of the study is
even lower if we postulate that the genotype B determines
a detrimental effect of experimental treatment compared
to control. Also in the case that the targeted population is
well represented, and the trial gives positive results in
favor of the new drug, this means that this effect is driven
by that subset of patients, anyway administering the treat-
ment to many patients who do not really benefit.
Moreover, the subgroup analysis process itself is biased by
many risks of data distortion. According to the brilliant paper
published by Lagakos et al, if you test 10 subgroups, your
chance to occur into more than 3, more than 2, and more than
1 false positive results is around 2%, 9% and 40% [29].
Any 'Post hoc' exploratory subgroup analyses (i.e. the
comparison of experimental and standard treatment sep-
arately in subgroups of patients identified by the biomar-
kers status, without a priori planned hypotheses) is a
dangerous procedure, because of the high risk of both
false positive and false negative results [30]. Importantly,
comparison of treatment and control should not be per-
formed separately in each subgroup, but formal test of
interaction should be performed [30]. Of course, results
of tests for interactions are likely to be convincing only if
they were specified at the start of the study. In any study
that presents subgroup analyses it is important to specify
when and why the subgroups were chosen [30,31]. With
all these considerations, the risk of mis-interpretation of
subgroup analyses, which is high by itself, does increase
when molecular characteristics are approached.
With regard to the last point, prospectively specified anal-
ysis plans for randomized phase III studies are fundamen-
tal to achieve reliable results. Paradoxically, many of the
currently ongoing trials for adjuvant treatment of resected
NSCLC are designed in order to select patients on the
basis of genetic features when 'old-fashioned' chemother-
apeutics are experimented (i.e. the Spanish Customized
Adjuvant Treatment, SCAT, randomizing patients on the
basis of BRCA overexpression, the and the International
TAilored Chemotherapy Adjuvant trial, ITACA, with a
two-step randomization taking into account both levels of
ERCC1 and TS tissue expression), and with a non-selec-
tion strategy, when adopting 'new and targeted' agents
(i.e. erlotinib and bevacizumab in the RADIANT, and in
the ECOG E1505 trial, respectively).
In an ideal scenario, when complete information on pre-
dictive factors and proper selection of patients can be def-
initely obtained in the early phases of drug development,
the conduction of subsequent phase III study could be
optimized. Unfortunately, this ideal scenario occurs
rarely, also with molecularly targeted agents. When plan-
ning a phase III trial comparing an experimental treat-
ment with the standard, we often have evidence
supporting a predictive role of a marker (M) about the
efficacy of the experimental treatment: according to that
evidence, patients with expression of the marker (M+) are
expected to potentially benefit of the experimental treat-
ment, and patients with absence of expression of the
marker (M-) are not [32]. In such a scenario, different
strategies based on prospective determination of marker
status are theoretically possible: (a) "randomize-all" strat-
egy, randomization between standard and experimental
treatment without selection, bu with stratification based
on the status of the marker; (b) "targeted" design, rand-
omization between standard and experimental treatment
only in patients selected according to the status of the
marker; (c) "customized" strategy (also called "marker-based
strategy"), randomization between standard arm, in which
the treatment is the same for all patients, and a personal-
ized arm, in which treatment is chosen based on the
marker status of each patient.
The "randomize-all" strategy is useful if investigators are
not sure of the complete lack of efficacy of experimental
treatment in M- patients. Marker is prospectively assessed
in all patients, allowing stratification, but all patients are
randomized, regardless of the marker status. Interaction
between marker status and treatment effect can be for-
mally tested by an interaction test. On the contrary, pre-
dictive role of the marker should not be addressed with
separate comparison in M+ and M- patients, because this
approach, as stated before, would be associated with a
high risk of false results [29].
An alternative strategy ("targeted design") is to test the sta-
tus of the marker M, randomizing only M+ patients. This
strategy is acceptable only in cases where investigators
have already enough evidence to completely rule out the
efficacy of the experimental treatment in M- patients. Due
to the absence of M- patients, targeted design allows inves-
tigators to avoid potential dilution of the results.
A third approach is the so-called "strategy design". Accord-
ing to this design, the experimental arm will receive a per-
sonalized treatment based on the status of predictive
marker, while all patients assigned to the control arm
receive standard treatment. A great limit of strategy design
is related to the proportion of M+ patients on the overall
number of patients. If M+ patients are a small minority,
treatment received will be nearly the same in both arms,Page 5 of 7
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cacy of experimental treatment. On the contrary, the strat-
egy design will be particularly effective when both M+ and
M- patients represent a significant proportion of the
patients.
Conclusion
The success of a targeted drug development (and the
patient benefit) strongly depends on extensive pre-clinical
and early clinical modeling, and so depends on conduct-
ing good science. Early phases, and in particular phase II
studies, remain crucial for development of targeted drug,
because this is the moment in which it is possible to
explore surrogate and potential selection biomarkers.
With these intents, phase II trials should be hypothesis-
generating and should signal either to progress to phase
III, and to go back to the lab. How clinical trial design
with molecularly targeted agents should be improved and
fasten to realize the real 'bench to bedside' medicine?
Molecularly targeted agents should be studied with those
early phases with the newest adaptive design [17], with a
more realistic basic hypotheses [33], and be 'tailored' on
a clearly specific molecular feature or signaling [34]. This
pivotal process, will come up into more accurate early
studies, providing few positive studies but with stronger
and more reliable results. Few drugs will enter the phase
III fashion, by increasing the chance to win over the stand-
ard. These following phase III trials (which remain always
mandatory), will be able to test more frequently superior-
ity hypotheses, providing big differences, less patients to
be enrolled, into shorter time for completing the studies.
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